Financial reports
Current reports
6-K
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
6 Jun 24
6-K
Current report (foreign)
5 Jun 24
6-K
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
23 May 24
6-K
Current report (foreign)
22 May 24
6-K
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
21 May 24
6-K
Annual General and Special Meeting
15 May 24
6-K
Current report (foreign)
14 May 24
6-K
Consolidated Financial Statements
8 May 24
6-K
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
2 May 24
6-K
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
11 Apr 24
Registration and prospectus
S-8
Registration of securities for employees
5 Apr 24
F-10/A
Registration of securities (Canada) (amended)
5 Feb 24
8-A12B
Registration of securities on exchange
18 Jan 24
F-X
Appointment of agent for service of process by issuers registering securities
18 Jan 24
F-10
Registration of securities (Canada)
18 Jan 24
D
$128.39 k in equity, sold $128.39 k, 3 investors
22 Aug 23
D
$37.95K in equity, sold $37.95K, 1 investor
18 Apr 16
D
$24.28K in equity, sold $24.28K, 1 investor
16 Sep 13
D
$23.78K in equity, sold $23.78K, 1 investor
11 Jul 13
D
$645.09K in equity / options / securities to be acquired, sold $376.85K, 14 investors
11 Jul 13
Proxies
No filings